VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) ("VIVO" or the "Company"), a leading provider of medical cannabis products and patient services, and holder of licences under the Cannabis Act through its wholly-owned subsidiaries, Canna Farms Limited ("Canna Farms") and ABcann Medicinals Inc., today announced the launch of new products under its Lumina™ health and wellness brand.

Lumina™ Ultralight 0:50 is a high cannabidiol (CBD) full-spectrum oil.

Lumina™ Spotlight 1:2 topical is a CBD-focused balanced topical with tetrahydrocannabinol (THC).

"VIVO is committed to delivering high quality medical cannabis products to our patients. Our latest Lumina™ range is a careful response to the direct feedback and insights we received from our patient base. We've developed these products and will continue to develop others to enhance patients' health and well-being," commented Ray Laflamme, Canna Farms' Co-Founder and VIVO's Chief Executive Officer. "With our latest Lumina™ product launches and our current line of Beacon Medical™ products, we continue to honour this commitment."

The expansion of Lumina™ medical cannabis oil and topical products for sale exclusively in the medical channel is part of VIVO's patient-first approach ensuring choice, access, and consistent supply for medical patients.

Both newly launched products are available to order now through the Canna Farms e-commerce medical marketplace for Canadian medical clients. Patients requiring support with registration or placing orders can contact VIVO's Customer Care Team at 1 (855) 882-0988 or This email address is being protected from spambots. You need JavaScript enabled to view it..

About VIVO Cannabis™

VIVO Cannabis™ is recognized for trusted, premium cannabis products and services. It holds production and sales licences from Health Canada and operates world-class indoor and seasonal airhouse cultivation facilities. VIVO has a collection of medical, health and wellness brands, each targeting different customer segments, including Canna Farms™, Beacon Medical™, Fireside™, and Lumina™. Harvest Medicine™, VIVO's patient-centric network of medical cannabis clinics, has serviced over 150,000 patient visits. VIVO is pursuing several partnership and product development opportunities and is focusing its international efforts on Germany and Australia. For more information visit: www.vivocannabis.com

For further information:

VIVO Investor Relations
+1 416-848-9839
This email address is being protected from spambots. You need JavaScript enabled to view it.

Instagram: https://www.instagram.com/vivo_cannabis/
Facebook: https://www.facebook.com/vivocanna/
Twitter: https://twitter.com/vivo_cannabis
LinkedIn: https://www.linkedin.com/company/vivo-cannabis-inc/

Disclaimer for Forward-Looking Information

Certain statements in this news release are forward-looking statements, which are statements that are not purely historical, including statements regarding the beliefs, plans, expectations or intentions of VIVO and its management regarding the future. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward‐looking statements. No assurance can be given that any of the events anticipated by the forward‐looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors carefully along with the more extensive risk factors included in the Company's most recent management's discussion and analysis available on SEDAR, in evaluating the forward‐looking statements contained in this news release and are cautioned not to place undue reliance on such forward‐looking statements, which are qualified in their entirety by these cautionary statements. The forward‐looking statements in this news release are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any such forward‐looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.